Menu
Visitors To Our Site
UNITED STATES
39.4%
39.4%UNITED KINGDOM
15.3%
15.3%RUSSIAN FEDERATION
5.2%
5.2%FRANCE
5.1%
5.1%ITALY
3.6%
3.6%BOSNIA AND HERZEGOVINA
3.4%
3.4%PORTUGAL
3.3%
3.3%SWEDEN
2.5%
2.5%REPUBLIC OF KOREA
2.5%
2.5%GERMANY
2.2%
2.2%NETHERLANDS
2.1%
2.1%CHINA
1.9%
1.9%GEORGIA
1.9%
1.9%BELGIUM
1.8%
1.8%SLOVENIA
1.7%
1.7%
Are you interested in joining our Global Colorectal Cancer Community? Please visit Global Colon Cancer.
You are here:
home
> news
News Articles
Please view the latest news articles from across Europe below. Alternatively, filter by news category or search by keyword.Roche Invests CHF190 Million In Herceptin Formulation Administration Device
Swiss pharmaceutical company Roche Holding AG (ROG.VX) said Wednesday, it is investing about 190 million Swiss francs ($183 million) at its production sites in Kaiseraugst, Switzerland, and Mannheim, Germany.
MAIN FACTS
-The production line in Kaiseraugst will provide the supply for clinical studies and market launch, and a full scale automated production line in Mannheim will deliver commercial supply to markets.
-The new infusion-free device will deliver an innovative Herceptin, or trastuzumab, formulation developed with Halozyme Therapeutics's "Enhanze" technology.
-This Herceptin formulation together with the ready-to-use administration device allows for injection of larger volumes of medicines into the tissue under the skin. Medicines which are currently administered by infusion in a hospital could therefore be self-administered via a subcutaneous injection.
For more details View the source article here
The information provided is for interest only and is not a substitute for professional medical advice. You should not rely on this information to make or refrain from making any decisions. Always obtain independent professional advice for your own particular health situation.
